(Source: American College of Cardiology Foundation) Editor's Note: This article by Dr. Tricoci is an excellent and comprehensive summary of significant studies supporting the indication for vorapaxar in vascular risk reduction as well as general comments about the protease-activated receptor 1 platelet/thrombin-inhibitor drug class. I believe you will find this an excellent reference source in that regard. George W. Vetrovec, MD, MACC Introduction Despite advances in antiplatelet therapy and the use of dual antiplatelet therapies in patients with acute coronary syndromes (ACS) and following coronary stent, the occurrence of recurrent ischemic events remains high. Current antiplatelet therapy...
↧